These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
400 related articles for article (PubMed ID: 30229376)
81. Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products. Cuende N; Ciccocioppo R; Forte M; Galipeau J; Ikonomou L; Levine BL; Srivastava A; Zettler PJ Cytotherapy; 2022 Jul; 24(7):686-690. PubMed ID: 35545453 [TBL] [Abstract][Full Text] [Related]
82. EVALUATION OF THE HTA CORE MODEL FOR NATIONAL HEALTH TECHNOLOGY ASSESSMENT REPORTS: COMPARATIVE STUDY AND EXPERIENCES FROM EUROPEAN COUNTRIES. Kõrge K; Berndt N; Hohmann J; Romano F; Hiligsmann M Int J Technol Assess Health Care; 2017 Jan; 33(6):644-653. PubMed ID: 29157316 [TBL] [Abstract][Full Text] [Related]
83. Incorporating option values into the economic evaluation of health care technologies. Palmer S; Smith PC J Health Econ; 2000 Sep; 19(5):755-66. PubMed ID: 11184803 [TBL] [Abstract][Full Text] [Related]
84. RESTORE Survey on the Public Perception of Advanced Therapies and ATMPs in Europe-Why the European Union Should Invest More! Goldsobel G; von Herrath C; Schlickeiser S; Brindle N; Stähler F; Reinke P; Aberman Z; Ofir R; Dessole G; Benvenuti S; Neves NM; Reis RL; Moll G; Volk HD Front Med (Lausanne); 2021; 8():739987. PubMed ID: 34765617 [TBL] [Abstract][Full Text] [Related]
85. Early dialogue with health technology assessment bodies: a European perspective. Cuche M; Beckerman R; Chowdhury CA; van Weelden MA Int J Technol Assess Health Care; 2014 Dec; 30(6):571-8. PubMed ID: 25816822 [TBL] [Abstract][Full Text] [Related]
86. Are Key Principles for improved health technology assessment supported and used by health technology assessment organizations? ; Neumann PJ; Drummond MF; Jönsson B; Luce BR; Schwartz JS; Siebert U; Sullivan SD Int J Technol Assess Health Care; 2010 Jan; 26(1):71-8. PubMed ID: 20059783 [TBL] [Abstract][Full Text] [Related]
87. CURRENT IMPLEMENTATION OF HEALTH TECHNOLOGY ASSESSMENT IN HEALTHCARE SYSTEM IN SLOVENIA. Prevolnik Rupel V Int J Technol Assess Health Care; 2017 Jan; 33(3):360-364. PubMed ID: 28434423 [TBL] [Abstract][Full Text] [Related]
88. SCIENTIFIC AND SOCIAL VALUE JUDGMENTS FOR ORPHAN DRUGS IN HEALTH TECHNOLOGY ASSESSMENT. Nicod E; Kanavos P Int J Technol Assess Health Care; 2016 Jan; 32(4):218-232. PubMed ID: 27624559 [TBL] [Abstract][Full Text] [Related]
89. Health technology assessment for gene therapies in haemophilia. O'Hara J; Neumann PJ; Haemophilia; 2022 Mar; 28 Suppl 2():19-26. PubMed ID: 35075731 [TBL] [Abstract][Full Text] [Related]
90. Regulatory Frameworks for Advanced Therapy Medicinal Products in Thailand. Boonprasirt P; Nimvorapun S; Sawangjang C; Poonpolsub S; Yoongthong W; Dunkum P Adv Exp Med Biol; 2023; 1430():221-233. PubMed ID: 37526851 [TBL] [Abstract][Full Text] [Related]
91. [HTA goes Europe: European collaboration on joint assessment and methodological issues becomes reality]. Nachtnebel A; Mayer J; Erdös J; Lampe K; Kleijnen S; Schnell-Inderst P; Wild C Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):291-9. PubMed ID: 26354129 [TBL] [Abstract][Full Text] [Related]
92. Practical tools and methods for health technology assessment in Europe: structures, methodologies, and tools developed by the European Network for Health Technology Assessment, EUnetHTA. Kristensen FB; Lampe K; Chase DL; Lee-Robin SH; Wild C; Moharra M; Garrido MV; Nielsen CP; Røttingen JA; Neikter SA; Bistrup ML; Int J Technol Assess Health Care; 2009 Dec; 25 Suppl 2():1-8. PubMed ID: 20030885 [TBL] [Abstract][Full Text] [Related]
93. HEALTH TECHNOLOGY ASSESSMENT OF MEDICAL DEVICES IN EUROPE: PROCESSES, PRACTICES, AND METHODS. Fuchs S; Olberg B; Panteli D; Busse R Int J Technol Assess Health Care; 2016 Jan; 32(4):246-255. PubMed ID: 27670589 [TBL] [Abstract][Full Text] [Related]
94. Health technology assessment for medical devices in Europe. What must be considered. Siebert M; Clauss LC; Carlisle M; Casteels B; de Jong P; Kreuzer M; Sanghera S; Stokoe G; Trueman P; Lang AW; Int J Technol Assess Health Care; 2002; 18(3):733-40. PubMed ID: 12391964 [TBL] [Abstract][Full Text] [Related]
95. An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2]. Garrison LP; Pauly MV; Willke RJ; Neumann PJ Value Health; 2018 Feb; 21(2):124-130. PubMed ID: 29477389 [TBL] [Abstract][Full Text] [Related]
96. Challenges to decision-making processes in the national HTA agency in Brazil: operational procedures, evidence use and recommendations. Yuba TY; Novaes HMD; de Soárez PC Health Res Policy Syst; 2018 May; 16(1):40. PubMed ID: 29751764 [TBL] [Abstract][Full Text] [Related]
97. State-of-the-art knowledge on the regulation of advanced therapy medicinal products. Kidpun P; Ruanglertboon W; Chalongsuk R Per Med; 2022 May; 19(3):251-261. PubMed ID: 35293224 [TBL] [Abstract][Full Text] [Related]
98. Social and ethical analysis in health technology assessment. Tantivess S J Med Assoc Thai; 2014 May; 97 Suppl 5():S81-6. PubMed ID: 24964703 [TBL] [Abstract][Full Text] [Related]
99. An equity framework for health technology assessments. Culyer AJ; Bombard Y Med Decis Making; 2012; 32(3):428-41. PubMed ID: 22065143 [TBL] [Abstract][Full Text] [Related]
100. The Relevance of Advanced Therapy Medicinal Products in the Field of Transplantation and the Need for Academic Research Access: Overcoming Bottlenecks and Claiming a New Time. Piemonti L; Scholz H; de Jongh D; Kerr-Conte J; van Apeldoorn A; Shaw JAM; Engelse MA; Bunnik E; Mühlemann M; Pal-Kutas K; Scott WE; Magalon J; Kugelmeier P; Berishvili E Transpl Int; 2023; 36():11633. PubMed ID: 37822447 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]